Cardium Therapeutics, Inc. (CDTP.OB): First Patient Enrolled in RAPID MI-ICE Study Employing INNERCOOL Therapies's Endovascular Temperature Modulation Therapy for Heart Attack
3/22/2007 12:17:56 PM
SAN DIEGO--(BUSINESS WIRE)--Cardium Therapeutics (OTCBB:CDTP) and its subsidiary InnerCool Therapies announced today the enrollment of the first patient in the RAPID MI-ICE study at Lund University Hospital in Sweden. The purpose of the study is to assess the safety and potential medical utility of early and rapid cooling of patients with myocardial infarction (MI or heart attack). Previous clinical data suggest early and rapid cooling with InnerCool’s endovascular catheter-based temperature modulation system immediately prior to reperfusion during angioplasty and stent procedures holds great promise for heart attack patients as a potential means of reducing cardiac tissue injury following reperfusion.